AT9283

Published: Nov 10, 2010 5:56 pm
Brand Name:
Generic Name:
Code Name: AT9283
Company: Astex
FDA Clinical Phase: 2

Description:

AT9283 is a kinase inhibitor that prevents cell division, thereby stopping the growth of cancer cells. Several Phase 1 clinical trials have shown that AT9283 is safe in patients with blood and solid-tumor cancers, and pre-clinical studies have indicated that AT9283, alone or in combination with other myeloma treatments, is effective in multiple myeloma cells.

Clinical Trials:
For a list of clinical trials studying AT9283 for the treatment of multiple myeloma, see ClinicalTrials.gov.

Website for AT9283: http://www.astex-therapeutics.com/products/pipeline.php

Related Articles: